Hideki Sakagami Selected Research

naquotinib

1/2020	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
1/2019	Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
1/2018	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideki Sakagami Research Topics

Disease

3	Neoplasms (Cancer) 01/2020 - 02/2014
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019 - 02/2014
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020
1	Fatty Liver 02/2016
1	Carcinoma (Carcinomatosis) 02/2014
1	Body Weight (Weight, Body) 02/2014

Drug/Important Bio-Agent (IBA)

3	naquotinibIBA 01/2020 - 01/2018
2	Tyrosine Kinase InhibitorsIBA 01/2019 - 01/2018
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	Choline (Choline Chloride)IBA 02/2016
1	Anaplastic Lymphoma KinaseIBA 02/2014
1	CrizotinibIBA 02/2014
1	Pemetrexed (MTA)FDA Link 02/2014
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2014
1	ASP3026IBA 02/2014

Therapy/Procedure

1	Therapeutics 01/2019